To determine whether DNMT1-mediated methylation landscape reprogramming can be used as a therapeutic strategy in synovial sarcoma, we performed a drug sensitivity test using decitabine or 5-AZA in a panel of different synovial sarcoma cell lines, with 2 untransformed mesenchymal cell lines (KCO2 or MSCs) as controls (Figure 3A). This evidence concerns the gene DNMT1 and synovial sarcoma.